WntResearch is active in biotechnology and is developing a therapy to counteract cancer metastases. The company's research is focused on studies of the body's own protein WNT5A, which has been seen in studies to affect the ability of tumor cells to move and spread. The company's drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is being evaluated in the phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer. The company was founded in 2007 and has its headquarters in Malmö.

Quotes for WntResearch AB

Right Now

+/-
0.25
%
1,55%
Latest
16.41
High
16.87
Low
16.25
Volume
13 663
Turnover (SEK)
227 180
Market Value (MSEK)
142,1
Time (Latest trade)

Board

CEO

  • Per Norlén

Chairperson of the Board

  • Christer Nordstedt

Board

  • Åsa Kornfeld
  • Gudrun Anstrén
  • Janna Sand-Dejmek
  • Mats Lindskog
  • Peter Ström
  • Tommy Andersson

Videos

Largest Owners

Name Capital % Votes % Date
Avanza Pension 11,53 11,53 2024-06-26
Nordnet Pensionsförsäkring 6,21 6,21 2024-06-26
Thomas Mellqvist 3,48 3,48 2024-06-26
Försäkringsaktiebolaget Skandia 2,50 2,50 2024-06-26
Niclas Evertsson 2,27 2,27 2024-06-26
Lars-Erik Forsgårdh 2,16 2,16 2024-06-26
Kjell Stenberg 2,14 2,14 2024-06-26
Stefan Malmkvist 1,73 1,73 2024-06-26
Psykolog JP Gisselgård AS 1,73 1,73 2024-06-26
Srch Quality Consulting AB 1,40 1,40 2024-06-26
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream